Medicine: Histone deacetylase inhibitor gel shows promise for the treatment of patients with basal cell carcinoma
Remetinostat, a topical cream and first-in-class inhibitor of histone deacetylation, showed signs of clinical efficacy in patients with basal cell carcinoma. Philadelphia, August 08, 2021.- Basal cell carcinoma (BCC) is the most common form of skin cancer and is typically treated with surgical excision, explained Sarin. «While BCC is notContinuar Leyendo















